摘要
目的:观察围产期心肌病患者的临床特点,分析治疗效果。方法:选择我院收治的64例围产期心肌病患者为研究对象,随机分为2组:对照组和治疗组。对照组:给予吸氧、利尿、扩血管、防血栓,抗心力衰竭等常规治疗:治疗组:在对照组治疗的基础上,给予替米沙坦和生脉注射液,疗程4周。比较2组患者的疗效及心功能变化.结果:治疗组患者的疗效明显优于对照组(P<0.05):治疗后心功能各参数均优于对照组(P<0.05)。结论:替米沙坦联合生脉注射液可改善围产期心肌病患者的心功能,疗效显著。
Objective： To observe the clinical features of patients with peripartum cardiomyopathy and analyze the curative effect. Methods： Sixty four patients with peripartum cardiomyopathy who came to our hospital were divided into two groups randomly： control group and treatment group. The control group accepted conventional therapy, such as oxygen uptake, diuresis, vasodilator reflex, anti thrombus and anti congestive heart failure. Based on the control group,the treatment group accepted telmisartan and pulse-activating injection. The course of treatment was four weeks. The treatment effect and heart function of two groups was compared.Results：The curative effect of treatment group was better than that of control group（P〈0.05）.The heart function parameter post-treatment was much better than that of control group（P〈0.05）.Conclusions：Telmisartan and !0ulse-activating injection can improve the heart function of patients with peripartum cardiomyopathy and has significant therapeutic effect.
出处
《中国医药导刊》
2011年第6期975-976,共2页
Chinese Journal of Medicinal Guide
关键词
围产期心肌病
生脉注射液
替米沙坦
Peripartum cardiomyopathy
Pulse-activating injection
Irbesartan
